Source: Annual Congress 2006 - Cardiovascular pathophysiology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Borak, I. Pabinger, I. M. Lang (Vienna, Austria). Prevalence of pulmonary hypertension in patients with plasma lupus anticoagulant. Eur Respir J 2006; 28: Suppl. 50, 2388

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of ²Korargin² in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018 Year: 2019 Endothelium dysfunction in systemic lupus erythematosus patients with pulmonary hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Early outcomes of patients with systemic lupus erythematosus and antiphospholipid syndrome after pulmonary endarterectomy Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Pulmonary hypertension in patients with lupus: Prevalence, etiology and risk factors Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Pulmonary arterial hypertension and systemic lupus erythematosus Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia Source: International Congress 2017 – PAH and CTEPH Year: 2017 Secondary pulmonary hypertension in chronic obstructive pulmonary disease and systemic lupus erythematosus- pathophysiology and treatment Source: Eur Respir J 2004; 24: Suppl. 48, 59s Year: 2004 Prevalence of lupus anticoagulant in patients undergoing bronchoscopy Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases Year: 2010 Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017 Year: 2018 Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Systemic inflammation and pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 142s Year: 2007 Prevalence of pulmonary hypertension in patients after splenectomy Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Prevalence of pulmonary hypertension in limited and diffuse scleroderma Source: Eur Respir J 2003; 22: Suppl. 45, 465s Year: 2003 The nitroxidergic system state at systemic lupus erythematosus-associated pulmonary hypertension Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Predictors of pulmonary artery hypertension in patients with systemic sclerosis Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Type of anticoagulant therapy as a risk factor for the severity of chronic thromboembolic pulmonary hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Pulmonary hypertension in systemic scleroderma Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003